Literature DB >> 7737253

A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological Group.

G A Dijkman1, F M Debruyne, P Fernandez del Moral, J W Plasman, J W Hoefakker, J G Idema, M Sykes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7737253     DOI： 10.1159/000475421

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  1 in total

1.  Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer.

Authors:  Shinzaburo Noguchi; Hee Jeong Kim; Anita Jesena; Vani Parmar; Nobuaki Sato; Hwei-Chung Wang; Santi Lokejaroenlarb; Jofel Isidro; Ku Sang Kim; Yohji Itoh; Eisei Shin
Journal:  Breast Cancer       Date:  2015-09-09       Impact factor: 4.239
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.